Temozolomide for high grade glioma

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 4, 2013, Pages

  Hart, Michael G ^a   Garside, Ruth ^b   Rogers, Gabriel ^c   Stein, Ken ^d   Grant, Robin ^e  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^c NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE   (United Kingdom)

^d PENINSULA MEDICAL SCHOOL   (United Kingdom)

^e WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE;

ADJUVANT THERAPY; AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; COMPARATIVE STUDY; FATIGUE; FEVER; GLIOBLASTOMA; GLIOMA; HEMATOLOGIC DISEASE; HUMAN; INFECTION; META ANALYSIS; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCYTOPENIA; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; SEIZURE; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; VOMITING; AGE; BRAIN TUMOR; CANCER GRADING; PATHOLOGY; SURVIVAL; TUMOR RECURRENCE;

AGE FACTORS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; GLIOBLASTOMA; HUMANS; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 84886855132     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007415.pub2     Document Type: Review

References (63)

1. Athanassiou H, Synodinou M, Maragoudakis E, Paraskevaidis M, Verigos C, Misailidou D, et al.Randomised phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. Journal of Clinical Oncology 2005;23(10):2372-77.
2. Brada M, Stenning S, Gabe R, Thompson LC, Levy D, Rampling R, et al.Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. Journal of Clinical Oncology 2010;28(30):4601-10.
3. Clarke JL, Iwamoto FM, Sul J, Panageas K, Lassman AB, DeAngelis LM, et al.Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. Journal of Clinical Oncology 2009;27(23):3861-7.
4. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al and European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups and National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology 2009;10(5):459-66.
5. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al.Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine 2005;352(10):987-96.
6. Taphoorn MJ, Stupp R, Coens C, Osoba D, Kortmann R, van den Bent MJ, et al.Health-related quality of life in patients with glioblastoma: A randomised controlled trial. Lancet Oncology 2005;6:937-44.
7. Kocher M, Frommolt P, Borberg SK, Ruhl U, Steingraber M, Niewald M, et al.Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma. Strahlentherapie und Onkologie 2008;184(11):572-9.
8. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinback JP, Sabel M, Combs SE, Vesper J, Brain C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M, for the NOA-08 Study Group of the Neuro-oncology Working Group (NOA) of the German Cancer Society. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 Randomised, phase 3 trial. Lancet Oncology 2012;13(7):707-715.
9. Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R, for the Nortic Clinical Brain Tumour Study Group (NCBTSG). Temozolomide versus standard 6-week radiotehrapy versus hypofractionated radiotherapy in patients older than 60 years with gliobalastoma: the Nordic randomised, phase 3 trial. Lancet Oncology 2012;13:916-926.
10. Osoba D, Brada M, Yung WKA, Prados MD. Health related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. Journal of Clinical Oncology 2000;18(7):1481-91.
11. Yung A, Levin VA, Albright A. Randomized trial of temodal (TEM) vs. procarbazine (PCB) in glioblastoma multiforme (GBM) at first relapse. Proceedings of the American Society of Clinical Oncology 2000;18:139.
12. Bogdahn U, Hau P, Stockhammer G, Venkataramana NK, Mahapatra AK, Suri A, et al. The Trabedersen Glioma Study Group. Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro-Oncology 2011;13(1):132-42.
13. Bower M, Newlands ES, Bleehen NM, Brada M, Begent RJ, Calvert H, et al.Multicentre CRC Phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer, Chemotherapy and Pharmacology 1997;40:484-8.
14. Gilbert MR, Wang M, Aldape K, Sorensen G, Mikkelsen T, Bokstein F, et al.RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan (CPT) or dose-dense temozolomide (TMZ) in recurrent glioblastoma (GBM). Neuro-Oncology. Montreal, QC, Canada, 2010; Vol. 12:iv39.
15. Hamilton DA. Adding concomitant and adjuvant temozolomide to radiotherapy dose not reduce health-related quality of life in people with glioblastoma. Cancer Treatment Reviews 2006;32(6):483-6.
16. Kim IH, Park C-K, Han J-H, Se-Hoon L, Chae YK, Tae MK, et al.Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial. Neuro-Oncology. Montreal, QC, Canada, 2010:iv51.
17. Lanzetta G, Campanella C, Rozzi A, Nappa M, Costa A, Fedele F, et al.Temozolamide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial. Anticancer Research 2003;23(6D):5159-64.
18. Lee S-M, Brada M, Stenning S, Thompson L, Gabe R. A randomised trial of procarbazine, CCNU and vincristine (PCV) vs temozolomide (5-day of 21-day schedule) for recurrent high grade glioma (MRC BR-12, ISRCTN83176944). Annals of Oncology. Stockholm, 2008; Vol. 19 (S8):viii2.
19. Linz U. Commentary on effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology 2009;10:459-66.
20. Malmstrom A, Poulsen HS, Stragliotto G, Gronberg B, Hansen S, Asklund T, et al.Neoadjuvant temozolomide for grade III and IV astrocytoma: a randomized phase II study. Neuro-Oncology 2010;12(iii):39-40.
21. Malmstrom A, Gronberg BH, Stupp R, Marosi C, Frappaz HP, Schultz M, et al.Glioblastoma (GBM) in elderly patients: a randomized phase III trial comparing survival in patients treated with 6-week radiotherapy (RT) versus hypofractionated RT over 2 weeks versus temozolomide single-agent chemotherapy. Journal of Clinical Oncology. Chicago, Il, United States, 2010; Vol. 28:18 Suppl 1.
22. Naboors LB. NABTT 0306: A randomized phase II trial of EMD 121974 in conjunction with concomitant and adjuvant temozolomide with radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM). Journal of Clinical Oncology: ASCO annual meeting proceedings 2009;27(15S Part 1):87.
23. Nayak L, Panageas KS, Deangelis LM, Abrey LE, Lassman AB. Radiotherapy (RT) and temozolomide (TMZ) for anaplastic astrocytoma (AA). Neuro-Oncology. Montreal, QC, Canada, 2010:iv77-78.
24. Newlands ES, O'Reilly SM, Glaser MG, Bower M, Evans H, Brock C, et al.The Charing Cross Hospital experience with temozolomide in patients with gliomas. European Journal of Cancer 1996;32A:2236-41.
25. Osoba D, Brada M, Yung WKA, Prados MD. Health related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. European Journal of Cancer 2000;36:1788-95.
26. Qian ZZ, Wang HQ, Liu XM, Yang SY, Fu Z, Chang Y, et al.A multicenter randomized controlled study of temozolomide in 97 patients with malignant brain glioma. Chinese Medical Journal 2009;89(29):2059-62.
27. Renard L, Clement PM, Hammoch F, Boterberg T, Verschaeve V, Whenham N, et al.Safety analysis of randomized Belgian phase II trial of extended use of adjuvant temozolomide in newly diagnosed glioblastoma patients. Neuro-Oncology. Maastricht, Netherlands, 2010.
28. Spiegel BMW, Esrailian E, Laine L, Chamberlain MC. Clinical impact of adjuvant chemotherapy in glioblastoma multiforme: a meta-analysis. CNS Drugs 2007;21(9):775-87.
29. Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, et al.Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolamide followed by adjuvant temozolamdide. Journal of Clinical Oncology 2002;20(5):1375-82.
30. van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC, Kros JM, Carpentier AF, et al.Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. Journal of Clinical Oncology 2009;27(8):1268-74.
31. Wang X-H, Guo L-Y, Ma B, Yang KH, Zhang QN, Cao N, et al.Radiotherapy combined with temozolomide treatment for glioblastoma multiforme: a meta-analysis. Tumour 2010;30(12):1056-64.
32. Weller M, Tabatabai G, Reifenberger G, Herrlinger U, Pichler J, Schnell O, et al.Dose-intensifed rechallenge with temozolomide: one week on/one week off versus 3 weeks on/one week off in patients with progressive or recurrent gliomblastoma. Journal of Clinical Oncology. 2010; Vol. 28:15 Supply 1.
33. Wick W, Hartmann C, Engel C, Stoffels, Felsberg J, Stockhammer F, et al.NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of Clinical Oncology 2009;27(35):5874-80.
34. Wick W. NOA-08 randomized phase III trial of 1-week-on/1-week-off temozolomide versus involved-field radiotherapy in elderly (older than 65) patients with newly diagnosed anaplastic astrocytoma or glioblastoma (Methusalem). Journal of Clinical Oncology 2010;28(18 Suppl):949.
35. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, et al.Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Journal of Clinical Oncology 1999;17(9):2762-71.
36. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, et al.A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. British Journal of Cancer 2000;83(5):588-593.
37. Keime-Guibert F, Chinot I, Taillandier L, et al.Radiotherapy for glioblastoma in the elderly. New England Journal of Medicine 2005;356:1527-1535.
38. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, et al.Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. Journal of Clinical Oncology 24;18:2707-14.
39. Castillo MS, Davis FG, Surawica T, Bruner JM, Bigner S, Coons S, et al.Consistency of primary brain tumor diagnoses and codes in cancer surveillance systems. Neuro-epidemiology 2004;23:85-93.
40. Counsell CE, Collie DA, Grant R. Incidence of intracranial tumours in the Lothian region of Scotland, 1989-90. Journal of Neurology, Neurosurgery & Psychiatry 1996;61(2):143-50.
41. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
42. Fowkes FGR, Fulton PM. Critical appraisal of published research: introductory guidelines. BMJ 1991;302:1136-40.
43. Giese A, Kucinski T, Knopp U, et al.Pattern of recurrence following local chemothereapy with biodegradeable carmustine (BCNU) implant in patients with glioblastoma. Journal of Neuro-oncology 2004;66:351-360.
44. Glioma Meta-Analysts Trialists (GMT) Group. Chemotherapy for high grade glioma. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD003913].
45. Grant R. Overview: brain tumour diagnosis and management/Royal College of Physicians Guidelines. Journal of Neurology, Neurosurgery and Psychiatry 2004;75(Suppl 2):18-23.
46. Hart MG, Grant R, Metcalfe SE. Biopsy versus resection for high grade glioma. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD002034].
47. Hart MG, Grant R, Garside R, Rodgers G, Somerville M, Stein K. Chemotherapy wafers for high grade glioma. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD007294].
48. Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
49. Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42-6.
50. Kaal ECA, Vecht CJ. The management of brain edema in brain tumours. Current Opinion in Oncology 2004;16:593-600.
51. Karnofksy DA. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948;1:634-56.
52. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathology 1993;3(3):255-68.
53. Louis DN, Ohgaki H, Wiestler OD, et al.The 2007 WHO classification of tumours of the central nervous system.. Acta Neuropathologica 2007;114:97-109.
54. Mauer ME, Bottomley A, Taphoorn MJB. Evaluating health-related quality of life and symptom burden in brain tumour patients: instruments for use in clinical trials and clinical practice. Current Opinion in Neurology 2008;21:741-53.
55. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature of endpoints. Statistics in Medicine 1998;17:2815-34.
56. Rampling R, James A, Papanastassoiu V. The present and future management of malignant brain tumours: surgery, radiotherapy, chemotherapy. Journal of Neurology, Neurosurgery and Psychiatry 2005;75(Suppl II):ii24-ii30.
57. Scottish Health Startistics. Brain and central nervous system cancer. http://www.isdscotland.org/Health-Topics/Cancer/Cancer-Statistics/Brain-and-Central-Nervous-System/. [http://estras.isdscotland.org/phpprint.php].
58. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, et al.Adjucant procarbazine, lomustine and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase II trial. Journal of Clinical Oncology 2006;24(18):2715-2722.
59. Velasquez-Perez L, Jimenez ME. Clinical-Histopathologic Concordance of Tumors of the Nervous System at the Manuel Velasco Suarez National Institute of Neurology and Neurosurgery in Mexico City. Archives of pathology and laboratory medicine 2002;127(2):187-192.
60. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, et al.Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. Journal of Neurosurgery 1978;49:333-43.
61. Walker M, Brown J, Brown K, Gregor A, Whittle IR, Grant R. Practical problems with the collection and interpretation of serial quality of life assessments in patients with malignant glioma. Journal of Neuro-Oncology 2003;63(2):179-86.
62. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al.Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group [Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM.]. Journal of Clinical Oncology 2010;28(11):1963-72.
63. Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K. Temozolomide for high grade glioma. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD007415].